Alembic announces successful USFDA inspection at joint venture
Aleor Dermaceuticals Ltd., a 60:40 joint venture between Alembic Pharmaceuticals Ltd. and Orbicular Pharmaceutical Technologies Pvt. Ltd., has successfully cleared its first US FDA inspection of its new formulation facility located at Karakhadi, Gujarat, without any observations. The scheduled inspection was carried out between October 15-19, 2018.
Aleor was formed in April 2016 to develop, manufacture and commercialise dermatology products for worldwide markets. Till date the company has filed six ANDAs.
“This is a result of the dedication, commitment and focus of the entire Aleor team to ensure highest quality standards are maintained and we are very excited to build this organisation on a global platform,” said Dr. M.S. Mohan, Founder and Managing Director of Orbicular.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-06-28
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
NHU and Sinopec Advance Liquid Methionine Project
-
Wall Street Predicts New Obesity Pills Will Be Priced Near $1000 Like Wegovy and Zepbound Supply and Competition Pressures Mount
-
Glenmark Targets 10–15 Percent CAGR in India by Shifting to High-Margin Drugs AbbVie Deal and New Launches Boost Outlook
-
Haryana’s Drug Crackdown Gets Massive Public Support State Launches Podcast to Boost Community Involvement
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
Indian Pharma Urges US to Exempt Generics as 50 Percent Tariffs Loom National Security Probe Sparks Supply Fears
-
EFSA Confirms Safety of Vitamin E TPGS as Food Additive New Opinion Covers Multiple Use Levels
-
EFSA Reaffirms Safety of E948 Oxygen and E949 Hydrogen in All Foods No Health Risks Detected
Recommend Reading
-
Mounjaro Usage Doubles in June Sales Surge by 18 in India
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
Pfizer Warns Germany: Drug Pricing Could Put Investment at Risk
-
J&J VAT Dispute Threatens Free Medicine Access in Britain
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
Santos Secures LNG Supply Deal with QatarEnergy for 1 Million Tons by 2028
-
Vietnam’s Seafood Exports Surge 20 Percent to $6.2 Billion China Hong Kong Overtakes US as Top Market Amid Trade Headwinds
-
Both Cost and Demand Weaken, PTA Prices Slightly Decline
-
FDA Issues Import Alert 99-38 for Guangxi Wuzhou Company Herbal Jelly Products Face Automatic Detention
-
Two Major Chemical Companies Collapse in May as the Global Industry Faces a Broad Downturn